BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, January 1, 2026
See today's BioWorld
Home
» Roivant inks $500M deal with Hanall for autoimmune candidate
To read the full story,
subscribe
or
sign in
.
Roivant inks $500M deal with Hanall for autoimmune candidate
Dec. 28, 2017
By
David Ho
HONG KONG – Roivant Sciences Ltd., of Basel, Switzerland, has inked a $502.5 million deal for an autoimmune treatment developed by South Korea's Hanall Biopharma Co. Ltd.
BioWorld
